Loading…
Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics
The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs...
Saved in:
Published in: | Journal of pharmaceutical and biomedical analysis 2011-07, Vol.55 (5), p.878-888 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793 |
---|---|
cites | cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793 |
container_end_page | 888 |
container_issue | 5 |
container_start_page | 878 |
container_title | Journal of pharmaceutical and biomedical analysis |
container_volume | 55 |
creator | Gupta, Shalini Devanarayan, Viswanath Finco, Deborah Gunn, George R. Kirshner, Susan Richards, Susan Rup, Bonita Song, An Subramanyam, Meena |
description | The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007
[1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors. |
doi_str_mv | 10.1016/j.jpba.2011.03.038 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_868376563</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0731708511001907</els_id><sourcerecordid>868376563</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</originalsourceid><addsrcrecordid>eNqFkV2L1DAUhoso7rj6B7zQ3IjedMx3UvBGFr9gQVAXvAtpejJmaJsxaRfGf-M_NaUzerdCICE85z05earqKcFbgol8vd_uD63dUkzIFrOy9L1qQ7RiNZX8-_1qgxUjtcJaXFSPct5jjAVp-MPqghLBiKB0U_3-Ai4OA4ydnUIcM_IxoekHoFvbh_UORY8c9H3d2gwdsjnbY0bzcj7DHUzgzuwI85RK9a8w7pAdp9DG7ojCMMwjoAT5UNpARtAHF6YlcGfDmCfUhtjHXXC2XzKTPZSc4PLj6oG3fYYnp_2yunn_7tvVx_r684dPV2-va8eVmGrGWy4bj5kkrQCrgEigsrXMK8uVdwxbYF0rOO2U1F5IgRU0jWq04JKphl1WL9fcQ4o_Z8iTGUJe5rYjxDkbLTVTUkhWyFd3kkQqLRiWivwfxVjrYquRBaUr6lLMOYE3hxQGm44FMotvszeLb7P4NpiVpUvRs1P-3A7Q_S05Cy7AixNgc_lZn-zoQv7HccobxUXhnq-ct9HYXSrMzdfSSWBMKJZ0mfrNSkCRcBsgmewCjA66kIp808Vw10v_AMgl1MY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1008826496</pqid></control><display><type>article</type><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><source>ScienceDirect Freedom Collection</source><creator>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</creator><creatorcontrib>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</creatorcontrib><description>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007
[1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</description><identifier>ISSN: 0731-7085</identifier><identifier>EISSN: 1873-264X</identifier><identifier>DOI: 10.1016/j.jpba.2011.03.038</identifier><identifier>PMID: 21531522</identifier><identifier>CODEN: JPBADA</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>Analysis ; Analytical, structural and metabolic biochemistry ; Animals ; Antibodies ; Antibodies, Neutralizing - immunology ; Antibody Formation ; Biological and medical sciences ; Biological Assay - methods ; Biological Products - immunology ; Blood Proteins - chemistry ; Cell-based assay ; Chemistry, Pharmaceutical - methods ; Chemistry, Pharmaceutical - standards ; Fundamental and applied biological sciences. Psychology ; General pharmacology ; Humans ; Immune response ; Immune System ; Immunogenicity assay ; Medical sciences ; NAb assay ; NAb assay validation ; neutralization ; Neutralization Tests ; neutralizing antibodies ; Neutralizing antibody bioassay ; Pharmaceutical Preparations ; Pharmacology. Drug treatments ; Reproducibility of Results ; Sensitivity and Specificity ; Serum-based bioassay ; Software ; therapeutics</subject><ispartof>Journal of pharmaceutical and biomedical analysis, 2011-07, Vol.55 (5), p.878-888</ispartof><rights>2011 Elsevier B.V.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</citedby><cites>FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24249745$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21531522$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gupta, Shalini</creatorcontrib><creatorcontrib>Devanarayan, Viswanath</creatorcontrib><creatorcontrib>Finco, Deborah</creatorcontrib><creatorcontrib>Gunn, George R.</creatorcontrib><creatorcontrib>Kirshner, Susan</creatorcontrib><creatorcontrib>Richards, Susan</creatorcontrib><creatorcontrib>Rup, Bonita</creatorcontrib><creatorcontrib>Song, An</creatorcontrib><creatorcontrib>Subramanyam, Meena</creatorcontrib><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><title>Journal of pharmaceutical and biomedical analysis</title><addtitle>J Pharm Biomed Anal</addtitle><description>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007
[1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</description><subject>Analysis</subject><subject>Analytical, structural and metabolic biochemistry</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antibodies, Neutralizing - immunology</subject><subject>Antibody Formation</subject><subject>Biological and medical sciences</subject><subject>Biological Assay - methods</subject><subject>Biological Products - immunology</subject><subject>Blood Proteins - chemistry</subject><subject>Cell-based assay</subject><subject>Chemistry, Pharmaceutical - methods</subject><subject>Chemistry, Pharmaceutical - standards</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>General pharmacology</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immune System</subject><subject>Immunogenicity assay</subject><subject>Medical sciences</subject><subject>NAb assay</subject><subject>NAb assay validation</subject><subject>neutralization</subject><subject>Neutralization Tests</subject><subject>neutralizing antibodies</subject><subject>Neutralizing antibody bioassay</subject><subject>Pharmaceutical Preparations</subject><subject>Pharmacology. Drug treatments</subject><subject>Reproducibility of Results</subject><subject>Sensitivity and Specificity</subject><subject>Serum-based bioassay</subject><subject>Software</subject><subject>therapeutics</subject><issn>0731-7085</issn><issn>1873-264X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNqFkV2L1DAUhoso7rj6B7zQ3IjedMx3UvBGFr9gQVAXvAtpejJmaJsxaRfGf-M_NaUzerdCICE85z05earqKcFbgol8vd_uD63dUkzIFrOy9L1qQ7RiNZX8-_1qgxUjtcJaXFSPct5jjAVp-MPqghLBiKB0U_3-Ai4OA4ydnUIcM_IxoekHoFvbh_UORY8c9H3d2gwdsjnbY0bzcj7DHUzgzuwI85RK9a8w7pAdp9DG7ojCMMwjoAT5UNpARtAHF6YlcGfDmCfUhtjHXXC2XzKTPZSc4PLj6oG3fYYnp_2yunn_7tvVx_r684dPV2-va8eVmGrGWy4bj5kkrQCrgEigsrXMK8uVdwxbYF0rOO2U1F5IgRU0jWq04JKphl1WL9fcQ4o_Z8iTGUJe5rYjxDkbLTVTUkhWyFd3kkQqLRiWivwfxVjrYquRBaUr6lLMOYE3hxQGm44FMotvszeLb7P4NpiVpUvRs1P-3A7Q_S05Cy7AixNgc_lZn-zoQv7HccobxUXhnq-ct9HYXSrMzdfSSWBMKJZ0mfrNSkCRcBsgmewCjA66kIp808Vw10v_AMgl1MY</recordid><startdate>20110715</startdate><enddate>20110715</enddate><creator>Gupta, Shalini</creator><creator>Devanarayan, Viswanath</creator><creator>Finco, Deborah</creator><creator>Gunn, George R.</creator><creator>Kirshner, Susan</creator><creator>Richards, Susan</creator><creator>Rup, Bonita</creator><creator>Song, An</creator><creator>Subramanyam, Meena</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>FBQ</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7S9</scope><scope>L.6</scope><scope>7X8</scope></search><sort><creationdate>20110715</creationdate><title>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</title><author>Gupta, Shalini ; Devanarayan, Viswanath ; Finco, Deborah ; Gunn, George R. ; Kirshner, Susan ; Richards, Susan ; Rup, Bonita ; Song, An ; Subramanyam, Meena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Analysis</topic><topic>Analytical, structural and metabolic biochemistry</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antibodies, Neutralizing - immunology</topic><topic>Antibody Formation</topic><topic>Biological and medical sciences</topic><topic>Biological Assay - methods</topic><topic>Biological Products - immunology</topic><topic>Blood Proteins - chemistry</topic><topic>Cell-based assay</topic><topic>Chemistry, Pharmaceutical - methods</topic><topic>Chemistry, Pharmaceutical - standards</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>General pharmacology</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immune System</topic><topic>Immunogenicity assay</topic><topic>Medical sciences</topic><topic>NAb assay</topic><topic>NAb assay validation</topic><topic>neutralization</topic><topic>Neutralization Tests</topic><topic>neutralizing antibodies</topic><topic>Neutralizing antibody bioassay</topic><topic>Pharmaceutical Preparations</topic><topic>Pharmacology. Drug treatments</topic><topic>Reproducibility of Results</topic><topic>Sensitivity and Specificity</topic><topic>Serum-based bioassay</topic><topic>Software</topic><topic>therapeutics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Shalini</creatorcontrib><creatorcontrib>Devanarayan, Viswanath</creatorcontrib><creatorcontrib>Finco, Deborah</creatorcontrib><creatorcontrib>Gunn, George R.</creatorcontrib><creatorcontrib>Kirshner, Susan</creatorcontrib><creatorcontrib>Richards, Susan</creatorcontrib><creatorcontrib>Rup, Bonita</creatorcontrib><creatorcontrib>Song, An</creatorcontrib><creatorcontrib>Subramanyam, Meena</creatorcontrib><collection>AGRIS</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Shalini</au><au>Devanarayan, Viswanath</au><au>Finco, Deborah</au><au>Gunn, George R.</au><au>Kirshner, Susan</au><au>Richards, Susan</au><au>Rup, Bonita</au><au>Song, An</au><au>Subramanyam, Meena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics</atitle><jtitle>Journal of pharmaceutical and biomedical analysis</jtitle><addtitle>J Pharm Biomed Anal</addtitle><date>2011-07-15</date><risdate>2011</risdate><volume>55</volume><issue>5</issue><spage>878</spage><epage>888</epage><pages>878-888</pages><issn>0731-7085</issn><eissn>1873-264X</eissn><coden>JPBADA</coden><abstract>The administration of biological therapeutics may result in the development of anti-drug antibodies (ADAs) in treated subjects. In some cases, ADA responses may result in the loss of therapeutic efficacy due to the formation of neutralizing ADAs (NAbs). An important characteristic of anti-drug NAbs is their direct inhibitory effect on the pharmacological activity of the therapeutic. Neutralizing antibody responses are of particular concern for biologic products with an endogenous homolog whose activity can be potentially dampened or completely inhibited by the NAbs leading to an autoimmune-type deficiency syndrome. Therefore, it is important that ADAs are detected and characterized appropriately using sensitive and reliable methods. The design, development and optimization of cell-based assays used for detection of NAbs have been published previously by Gupta et al. 2007
[1]. This paper provides recommendations on best practices for the validation of cell-based NAb assay and suggested validation parameters based on the experience of the authors.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>21531522</pmid><doi>10.1016/j.jpba.2011.03.038</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0731-7085 |
ispartof | Journal of pharmaceutical and biomedical analysis, 2011-07, Vol.55 (5), p.878-888 |
issn | 0731-7085 1873-264X |
language | eng |
recordid | cdi_proquest_miscellaneous_868376563 |
source | ScienceDirect Freedom Collection |
subjects | Analysis Analytical, structural and metabolic biochemistry Animals Antibodies Antibodies, Neutralizing - immunology Antibody Formation Biological and medical sciences Biological Assay - methods Biological Products - immunology Blood Proteins - chemistry Cell-based assay Chemistry, Pharmaceutical - methods Chemistry, Pharmaceutical - standards Fundamental and applied biological sciences. Psychology General pharmacology Humans Immune response Immune System Immunogenicity assay Medical sciences NAb assay NAb assay validation neutralization Neutralization Tests neutralizing antibodies Neutralizing antibody bioassay Pharmaceutical Preparations Pharmacology. Drug treatments Reproducibility of Results Sensitivity and Specificity Serum-based bioassay Software therapeutics |
title | Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T01%3A28%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recommendations%20for%20the%20validation%20of%20cell-based%20assays%20used%20for%20the%20detection%20of%20neutralizing%20antibody%20immune%20responses%20elicited%20against%20biological%20therapeutics&rft.jtitle=Journal%20of%20pharmaceutical%20and%20biomedical%20analysis&rft.au=Gupta,%20Shalini&rft.date=2011-07-15&rft.volume=55&rft.issue=5&rft.spage=878&rft.epage=888&rft.pages=878-888&rft.issn=0731-7085&rft.eissn=1873-264X&rft.coden=JPBADA&rft_id=info:doi/10.1016/j.jpba.2011.03.038&rft_dat=%3Cproquest_cross%3E868376563%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c475t-34b469f0361b5ea7e16e26ba3f7a47fc30ae3db542d768f56507e997985463793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1008826496&rft_id=info:pmid/21531522&rfr_iscdi=true |